Cyclacel Pharmaceuticals (STU:UXI) Financial Strength : 4 (As of Sep. 2024)

Competitive Comparison of Cyclacel Pharmaceuticals's Financial Strength

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclacel Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Financial Strength distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Financial Strength falls into.

Cyclacel Pharmaceuticals Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Cyclacel Pharmaceuticals's Interest Expense for the months ended in Sep. 2024 was €0.01 Mil. Its Operating Income for the months ended in Sep. 2024 was €-1.96 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil.

Cyclacel Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2024 is

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Cyclacel Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Sep. 2024 is

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Cyclacel Pharmaceuticals has a Z-score of -123.13, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -123.13 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclacel Pharmaceuticals  (STU:UXI) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Cyclacel Pharmaceuticals has the Financial Strength Rank of 4.

Cyclacel Pharmaceuticals Financial Strength Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals Business Description